IC
CNSP icon

Ikarian Capital’s CNS Pharmaceuticals CNSP Stock Holding History

Ikarian Capital’s Portfolio CNSP Stock Details CNSP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$649K Buy
135,830
+90,000
+196% +$378K 0.07% 117
2026
Q1 		$110K Hold
45,830
– – 0.01% 148
2025
Q4 		$241K Buy
+45,830
New +$344K 0.02% 150

Other funds holding CNSP

ACM
ADAR1 Capital Management Austin, Texas $2.19B AUM 374.99% 1-Year Est. Return
SCM
Stonepine Capital Management Bend, Oregon $177M AUM 91.13% 1-Year Est. Return
BFM
Boothbay Fund Management New York $7.6B AUM 109.3% 1-Year Est. Return
Vanguard Fiduciary Trust
Vanguard Fiduciary Trust Malvern, Pennsylvania $454B AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
TRCT
Tower Research Capital (TRC) New York $4.08B AUM 58.77% 1-Year Est. Return
Barclays
Barclays London, United Kingdom $521B AUM 51.41% 1-Year Est. Return
BC
Barrett & Company Providence, Rhode Island $357M AUM 22.45% 1-Year Est. Return
DB
Danske Bank Copenhagen K, Denmark $50.6B AUM 42.84% 1-Year Est. Return

Ikarian Capital's CNSP Position: Q2 2026 in Review

Ikarian Capital increased its CNS Pharmaceuticals (CNSP) stake by 196% in Q2 2026, buying an estimated $378K and bringing the position to 135,830 shares worth $649K. The position accounts for 0.07% of the portfolio, ranked #117.

Ikarian Capital first reported a position in CNSP in Q4 2025 and has held it in 3 quarters since. 11 funds tracked by Wall St. Rank hold CNSP as of Q2 2026.

  • Ikarian Capital held 135,830 shares of CNS Pharmaceuticals worth $649K as of Q2 2026.
  • Ikarian Capital bought 90,000 CNS Pharmaceuticals shares in Q2 2026, an estimated $378K.
  • CNS Pharmaceuticals made up 0.07% of Ikarian Capital's portfolio in Q2 2026, its #117 holding.
  • Ikarian Capital first reported a position in CNS Pharmaceuticals in Q4 2025 and has held it in 3 quarters since.
  • 11 funds tracked by Wall St. Rank held CNS Pharmaceuticals as of Q2 2026.

Based on Ikarian Capital's 13F filing for Q2 2026, filed 14 Aug 2026.